1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Amgen's Blincyto on path to broader ALL indication

 
• By Alexandra Shimmings

Amgen has a broader indication for its acute lymphocytic leukemia (ALL) treatment Blincyto (blinatumomab) in its sights after top-line Phase II data looked positive in adults with relapsed or refractory Philadelphia chromosome-positive (Ph+) B-cell precursor ALL.

Amgen has a broader indication for its acute lymphocytic leukemia (ALL) treatment Blincyto (blinatumomab) in its sights after top-line Phase II data looked positive in adults with relapsed or refractory Philadelphia chromosome-positive (Ph+) B-cell precursor ALL.

The bispecific CD19-directed CD3 T cell engager (BiTE) antibody construct product became the first single-agent immunotherapy to be approved by...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By Kevin Grogan

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: Organon To Pull Plug On OG-6219 Program After Phase II Endometriosis Trial Failure

 
• By Sushmita Panda

Once hailed as a potential game changer, OG-6219 gets the axe after failing in a Phase II endometriosis-related pain trial.

In Brief: 4DMT Fast-Tracks Long-Acting Wet AMD Therapy Trials, Cuts 25% Of Workforce

 
• By Sushmita Panda

4D Molecular Therapeutics has fast-tracked its Phase III trials for 4D-150 in wet AMD, with top-line data from one now expected in H1 2027 and another underway ahead of schedule. The company is also cutting a quarter of its staff as it focuses on its late-stage pipeline and to help fund the trials.

In Brief: Atai-Beckley Deal Marches On After Phase II Psychedelic Win

 
• By Manas Mishra

The psychedelic therapy firms pass a key condition for their planned merger after the antidepressant BPL-003 meets the main endpoints of a Phase IIb trial.

More from R&D

In Brief: Atai-Beckley Deal Marches On After Phase II Psychedelic Win

 
• By Manas Mishra

The psychedelic therapy firms pass a key condition for their planned merger after the antidepressant BPL-003 meets the main endpoints of a Phase IIb trial.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By Kevin Grogan

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

In Brief: Opus Gears Up For FDA Filing In Presbyopia

 
• By Sushmita Panda

Data from a second pivotal trial support a filing in the US for Opus Genetics’ phentolamine ophthalmic solution, to treat presbyopia.